| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866590 | CEPHALON | Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation |
Apr, 2016
(8 years ago) | |
| US5958951 | CEPHALON | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
Jun, 2017
(6 years ago) | |
Gabitril is owned by Cephalon.
Gabitril contains Tiagabine Hydrochloride.
Gabitril has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Gabitril are:
- US5866590
- US5958951
Gabitril was authorised for market use on 16 April, 1999.
Gabitril is available in tablet;oral dosage forms.
The generics of Gabitril are possible to be released after 10 June, 2017.
Drugs and Companies using TIAGABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 1999
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of GABITRIL before it's drug patent expiration?
More Information on Dosage
GABITRIL family patents
